Investment trust insider on RTW Biotech – James Carthew: RTW Biotech will succeed with or without Arix
I was singing the praises of capital markets days last week. Last Tuesday, I managed to get along to one held by RTW Biotech Opportunities (RTW). The day was planned some time ago, but the timing was great as it gave the managers a chance to discuss the recently announced plan to merge RTW and Arix Bioscience (ARIX).
The management team behind RTW are largely North American but, when they launched the trust back in 2019, there was an intent to create a new UK base for their business to complement what they do elsewhere in the world.
The first speaker panel focused on the opportunity in the UK. We have four of the leading medical schools in the world and a great track record of cutting-edge bioscience in universities up and down the country. What we are not good at is turning those ideas into great British companies.
The problem is a lack of growth capital. You need a lot of time and money to shepherd a promising therapy from initial results in the lab, through clinical trials and to launch. There will be plenty of failures along the way, but success brings real rewards – both financial and medical.
read more here